United States · Platforms & data · MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

Published by MarketBeat · United States 59 min ago

Morgan Stanley increased their price objective on Kymera Therapeutics from $135.00 to $146.00 and gave the stock an "overweight" rating in a research report on Tuesday.

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

The Motley Fool

Here's How Much a $10,000 Investment in Realty Income Will Get You in Monthly Dividends

MarketWatch

My wife cried when I found out she had only $80,000 in her 401(k). I have $2.2 million. Am I wrong to be shocked?

Benzinga

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

Share

Also worth reading

Here's How Much a $10,000 Investment in Realty Income Will Get You in Monthly Dividends

My wife cried when I found out she had only $80,000 in her 401(k). I have $2.2 million. Am I wrong to be shocked?

Best Stocks Under $5

Novartis Raises Guidance After Trial Setbacks Hit Profit

Walmart copies a core Costco move that also benefits customers

ATOSS Software Q3 2026 Earnings Call Is Live